Other defects, which are not detectable with routine coagulation screening tests, are vitamin C deficiency and extremely rare fibrinolytic disorders, e.g., α2−antiplasmin and PAI deficiency.
Routine coagulation screening, including platelet count, International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), levels of coagulation factors II, V, VII and X, and fibrinogen, were measured daily for the first 3 days and upon discharge.
Deficiencies in these proteins are often undiagnosed for decades and detected later in life during routine coagulation assays without an apparent clinical phenotype.
Routine coagulation markers were measured.
Coagulation screen to determine: (a) Platelet count (b) Haemoglobin concentration .
There is no correlation between routine coagulation values and platelets at admission.
The relationship between routine coagulation parameters and platelet count has not been explored.
Routine coagulation studies, plasma antithrombin III, factor V, plasminogen, beta-thromboglobulin, fibrinopeptide A, prothrombin fragment F1+2, and thrombin-antithrombin III complex were all within normal limits.
NOACs offer several advantages compared with standard agents, including rapid onset of action, fixed dosing, and no requirement for routine coagulation monitoring.
However, it is associated with rates of deep venous thrombosis (DVT) of approximately 38%to55%5% and requires routine coagulation monitoring and frequent dose adjustment.
